

# Robert S Epstein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/15031/publications.pdf>

Version: 2024-02-01

10  
papers

152  
citations

1478505

6  
h-index

1372567

10  
g-index

11  
all docs

11  
docs citations

11  
times ranked

133  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors. <i>Advances in Therapy</i> , 2020, 37, 3606-3618.	2.9	52
2	Attitudes and Perceptions Toward COVID-19 Digital Surveillance: Survey of Young Adults in the United States. <i>JMIR Formative Research</i> , 2021, 5, e23000.	1.4	22
3	Patient Preferences for Change in Symptoms Associated with Opioid-Induced Constipation. <i>Advances in Therapy</i> , 2014, 31, 1263-1271.	2.9	18
4	Cancer Patients's Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 453-465.	1.8	14
5	When People with Opioid-Induced Constipation Speak: A Patient Survey. <i>Advances in Therapy</i> , 2017, 34, 725-731.	2.9	13
6	Real-world burden of chemotherapy-induced myelosuppression in patients with small cell lung cancer: a retrospective analysis of electronic medical data from community cancer care providers. <i>Journal of Medical Economics</i> , 2022, 25, 108-118.	2.1	11
7	Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 801-807.	1.9	10
8	Treatment patterns and burden of myelosuppression for patients with small cell lung cancer: A SEER's Medicare study. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100555.	1.7	5
9	Real-world burden of myelosuppression in patients with small cell lung cancer (SCLC): Retrospective, longitudinal data analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19300-e19300.	1.6	4
10	Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 670-679.	0.4	2